Biotech Values

[swampboots]

The absolute knowledge that no drug can be proven to ever fail under any future circumstance aways imbeds a (marketable) positive bias after dismal drug trial failures.
Exhibit A:
RE: Pembrolizumab, sold under the brand name Keytruda, now first line treatment of numerous metastatic cancers,( having generated over 17 billion in revenues to date ). In early 2010, Merck terminated development and began preparing to out-license it...................in short it was only the knowledge of limiting its use with patients matching biomarker criteria which made Merck start from almost scratch to get into this field in major depth, as this drug only came as an incidental package in buyout from Schering-Plough, and in 2013 for its first time, Merck applied for and won a breakthrough therapy designation for it.

https://en.wikipedia.org/wiki/Pembrolizumab